Oncology prior authorization at Humana
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Humana oncology PA at a glance
Humana reviews oncology PA submissions against its medical policy library, with rules drawn primarily from NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet — what to send
- Histologic diagnosis with ICD-10-CM code
- Stage at diagnosis + current line of therapy
- Biomarker test result with date and lab
- Prior systemic therapies tried, response, and reason for discontinuation
- Performance status (ECOG or KPS)
- NCCN-supported indication with version number
Common denial patterns to pre-empt
Patterns observed in oncology across payers, and where Humana's book of business overlaps:
- Off-label use not in FDA label
- Step therapy on biosimilar before reference biologic
- Site-of-care reduction (home infusion vs hospital)
- Frequency or duration outside policy
- Companion diagnostic not documented (HER2, PD-L1, MSI, BRCA, etc.)
- MA plan step therapy on Part B drugs
- OON emergency reduction
Appeal angles when Humana denies
- NCCN Compendium Category 1/2A citation for off-label support
- Pivotal trial citation by name with FDA approval date
- Genomic biomarker documentation (FoundationOne, Guardant360, MSK-IMPACT)
- Tumor board recommendation
Peer-to-peer prep
- Have the NCCN page reference open on screen (version + page #)
- Open the patient's biomarker report alongside the chart
- Lead with the FDA-approved indication; pivot to NCCN if at the edge of the label
- State the line of therapy explicitly (1L, 2L, 3L) — common point of P2P misunderstanding
Drug-specific PA criteria at Humana
Deep dives on each drug's PA criteria at Humana:
Frequently asked questions
What documentation does Humana need for oncology prior authorizations?
Humana's PA packet for oncology typically includes: Histologic diagnosis with ICD-10-CM code; Stage at diagnosis + current line of therapy; Biomarker test result with date and lab; Prior systemic therapies tried, response, and reason for discontinuation. NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium citations strengthen the submission.
What's the turnaround at Humana?
Humana standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Medicare Advantage extension rule under 42 CFR Part 422 may add 14 days. Internal appeal window if denied: 60 days.
Which oncology drugs does Humana most often PA-restrict?
Top targets in oncology: pembrolizumab, rituximab, trastuzumab, bevacizumab, nivolumab. Each follows the per-drug step therapy + documentation requirements published in Humana's medical policy library.
How do I prep a peer-to-peer with Humana in oncology?
Have the NCCN page reference open on screen (version + page #) Open the patient's biomarker report alongside the chart Have the policy URL and the patient's chart open before the call.
Generate a Oncology PA packet
Open ApprovalHelp — generate a oncology PA packet tailored to Humana's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com